Daryl Tan

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 788 citations

Medicine, Pharmacology, Pharmacotherapy +15

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase

Yok‐Lam Kwong, Thomas S. Y. Chan, Daryl Tan et al. · Blood · 2017 · 495 citations · Full text

Life Sciences, Immunology, Oncology +14

Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma

Ghee Chong Koo, Soo‐Yong Tan, Tiffany Tang et al. · Cancer Discovery · 2012 · 274 citations · Full text

Life Sciences, Cell Biology, Oncology +15

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

Daryl Tan, Sandra J. Horning, Richard T. Hoppe et al. · Blood · 2013 · 262 citations · Full text

Medicine, Oncology, Pathology +13

Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study

Jae Hoon Lee, Jin Seok Kim, Chang Ki Min et al. · American Journal of Hematology · 2014 · 123 citations · Full text

Medicine, Hematology, Oncology +15